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Abstract
The mitogen-activated protein (MAP) kinase ERK plays a key role in the regulation of cellular
proliferation. Mutations in the ERK cascade occur in 30% of malignant tumors. Thus understanding
how the kinase identifies its cognate substrates as well as monitoring the activity of ERK is central
to cancer research and therapeutic development. ERK binds to its protein targets, both downstream
substrates and upstream activators, via a binding site distinct from the catalytic site of ERK. The
substrate sequences that bind, or dock, to these sites on ERK influence the efficiency of
phosphorylation. For this reason, simple peptide substrates containing only phosphorylation
sequences typically possess low efficiencies for ERK. Appending short docking peptides derived
from full-length protein substrates and activators of ERK to a phosphorylation sequence increased
the affinity of ERK for the phosphorylation sequence by as much as 200-fold, while only slightly
diminishing the maximal velocity of the reaction. The efficiency of the phosphorylation reaction was
increased by up to 150 fold, while the specificity of the substrate for ERK was preserved. Simple,
modular peptide substrates which can be easily tailored to possess high phosphorylation efficiencies
will enhance our understanding of the regulation of ERK and provide a tool for the development of
new kinase assays.
INTRODUCTION
Mitogen-activated protein (MAP) kinases which include the extracellular signal regulated
kinases (ERKs), c-Jun N-terminal kinases (JNKs) and p38 kinases are key regulators of cell
proliferation and stress survival (1,2). Increases in MAP kinase activity have been linked to
proliferative disorders including cancer (3–6). In particular activation of ERK is implicated in
breast, ovarian and prostate cancers (7). The activation of ERK is initiated by a cascade of
sequentially activated proteins. The Ras G-proteins (H, K, and N-Ras) phosphorylate and
activate Raf kinases (A, B, and C-Raf) which in turn phosphorylate the MAP kinase kinases 1
and 2 (MEK1 and 2). MEK1 and 2 phosphorylate and activate the MAP kinase ERK (2,8).
Activated ERK phosphorylates a number of substrates including ribosomal proteins S6 kinases
(RSKs) and transcription factors, for example, the ETS family of proteins that control and
regulate cell growth and differentiation (9–13). As with other MAP kinases, ERK is a compact
kinase without additional regulatory domains. The activity of ERK is tightly controlled by the
phosphorylation of both a tyrosine and threonine residue in the activation loop (14–16). With
multiple MAP kinases present in the same cellular space, mechanisms must exist to prevent
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the factors controlling the specificity and efficiency of ERK are not fully understood. Analysis
of protein and peptide substrates demonstrate that ERK is a proline-directed serine or threonine
kinase with a phosphorylation consensus motif of Ser/Thr-Pro (12,17). However, this motif
alone is insufficient to explain the efficiency and specificity of ERK for its substrates, since
other MAP kinases (p38 kinase and JNK) as well as cyclin dependent kinases (CDKs) also
phosphorylate a similar consensus motif (17).
The specificity and efficiency of MAP kinases for their substrates is thought to be determined
by high-affinity, binding motifs on the protein substrate that are distinct from the consensus
phosphorylation sequence (18–31). One of the earliest identified binding or docking motifs
was the delta domain on the transcription factor c-Jun which mediates the high affinity binding
of the MAP kinase JNK to c-Jun (32,33). Various mutagenic and crystallographic studies have
now identified discrete sequences of amino acids or docking motifs on many of the substrates
of the MAP kinases. These docking motifs on the substrates are responsible for the specific
interactions of the substrate with its appropriate MAP kinase (19–31). In addition docking
motifs on the substrates of ERK increase the efficiency of phosphorylation of the substrate
(18,21–24,28–31,34). The major docking motif on ERK substrates is the D domain which
possesses a consensus sequence (Arg/Lys)2–3-(X)1–6-φA-X-φB; where φA and φB are
hydrophobic residues such as Leu, Ile, Val and X is any amino acid (18,21,22,24,27,29). The
D motifs in ERK-binding proteins (substrates, MAP kinase kinases, and ERK phosphatases)
bind to a complementary docking site on ERK composed of a highly acidic patch and a
hydrophobic groove located on the opposite face of the kinase relative to the catalytic site
(18,22,24,27,29). Docking motifs have been identified in substrates of p38 and JNK which are
similar but distinct from the docking domain on substrates of ERK. Mutating residues in the
docking region of ERK to those found in p38 kinase or JNK changes the specificity of ERK
to that of p38 or JNK respectively. Mutation of specific residues on ERK, for example, two
threonine residues in the acidic patch binding to the substrate D domain enables ERK to
phosphorylate substrates of the MAP kinase p38α and reduces the efficiency of
phosphorylation of ERK substrates (24).
Biochemical and structural studies of docking interactions between MAP kinases and their
substrates are key to developing a clear understanding of how MAP kinases recognize and
efficiently phosphorylate appropriate substrates while rejecting inappropriate substrates. A
goal of this work was to demonstrate a simple model system which yielded insights into the
role of the docking interactions between ERK and its binding partners. Docking peptides
derived from the D domain of downstream substrates or upstream kinase activators were linked
to a peptide possessing the consensus phosphorylation sequence and the contribution of each
component to the binding affinity and the rate of phosphate transfer was assessed. Since short
peptides with the phosphorylation consensus sequence alone, possess low affinity (KM>100
μM) for ERK compared to full length substrate proteins, current peptide substrates are limited
largely to assays of purified enzyme for which the enzyme concentration can be controlled and
no competing enzymes are present. Thus a second goal was to determine whether the designed
docked peptides could serve as high efficiency peptide substrates for ERK (35,36).
Development of efficient peptide substrates for ERK and other MAP kinases will yield new
opportunities in the development of kinase assays. These substrates would broaden the range
of peptide-based in vitro assays to utilize impure enzyme (cell lysates and tissue homogenates)
and serve as a basis for the development of new kinase indicators to monitor ERK activity in
intact cells. A wider range of FRET-based kinase indicators than that currently available would
be enabled by the development of simple yet efficient peptide substrates for kinases that rely
on docking interactions. For example, the FRET-based indicator strategy pioneered by Tsien
and others incorporates a peptide substrate sequence between two fluorescent proteins and
adjacent to a phosphopeptide-binding motif (37). Others methods use phosphorylation of a
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peptide-based substrate to assist in reassembly of between a circularly permutated fluorescent
protein. These methods have been very successful for kinases such as protein kinase C and A
which derive much of their specificity from the residues surrounding the phosphorylation
residue; however, the strategies are difficult to implement for kinases that derive the majority
of their efficiency and specificity from docking sites distant from the phosphorylated residue
(38). Efficient peptide substrates for ERK and other similar kinases would open the door to the
development of new FRET-based indicators of this type. A second class of kinase indicators
that rely on efficient peptide-based substrates are those developed by Lawrence and colleagues
(39). These probes have high value in measurements on primary cells since they are not
genetically encoded. Similarly short peptide substrates have been used by Allbritton and
colleagues to report intracellular kinase activity and this method would also benefit from the
development of efficient peptide-based substrates for use as reporters of cellular enzyme
activity (40).
RESULTS AND DISCUSSION
Components of the Designed ERK Substrates
A series of peptide substrates consisting of four modules was designed. The first module was
a fluorophore, fluorescein (5-FAM), used for detection and quantitation of the peptides. The
second component was a peptide matching the ERK consensus phosphorylation motif and
possessing a serine as the phosphoacceptor. The third piece was a peptide composed of the D
domain docking sequence from either upstream activators of ERK (MAP kinase kinases) or
downstream substrates of ERK. The final module was a linker bridging the docking peptide
and the substrate peptide. The phosphorylation sequence selected was “TGPLSPGPF”. This
peptide was predicted to be the optimal peptide sequence for ERK by Songyang et al using an
oriented, degenerate, peptide library (17). The sequence “TGPLSPGPF” possesses the
minimum consensus motif Ser/Thr-Pro found in ERK substrates such as tyrosine hydroxylase
and epidermal growth factor (12,17). In addition, it also contains Pro at the -2 position which
enhances the Vmax of peptide phosphorylation by ERK (41). The affinity (KM), and the catalytic
constant (kcat) of a similar peptide “ATGPLSPGPFGRR” for ERK2 are 450 ± 230 μM and
120 ± 8 min−1 respectively (35).
Selection of the Docking Peptides
The docking peptides were derived from the D domains of proteins with a range of binding
affinities for ERK. Since the D domains of upstream activators of ERK play a major role in
their binding to ERK, peptides derived from these domains may also exhibit enhanced binding
to ERK (21,28,42). A docking peptide derived from the N-terminal 13 amino acids of the MAP
kinase kinase MEK1 (1 MPKKKPTPIQLNP13) was chosen since MEK1 binds ERK2 with an
affinity of 29 μM (28). A docking peptide derived from the N-terminal 16 amino acids of MEK2
(1 MLARRKPVLPALTINP16) was utilized as a potential intermediate-affinity peptide since
MEK2 possesses an affinity of 9 μM for ERK2 (28). STE7, a MAP kinase kinase, from the
yeast Saccharomyces cerevisiae interacts with mammalian ERK1 and ERK2 with a KD of 1
μM. Thus a peptide comprised of the N-terminal 18 amino acids (2
FQRKTLQRRNLKGLNLNL19) was employed as a potential, higher-affinity binding peptide
than the peptide derived from MEK2 (28). A fourth, docking
peptide, 310PQKGRKPRDLELPL323 was derived from the N-terminal 14 amino acids of the
transcription factor ELK1, a substrate of ERK. The affinity for ERK of the ELK1 protein
without the FXFP motif is 5μM (21)
Selection of the Linker Composition
A linker was used to bridge the docking peptide to the substrate peptide since the D domain-
binding site and catalytic cleft on ERK are not immediately adjacent to one another (Figure 1,
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panel a). The linker also permitted the docking peptide and substrate to have flexibility in their
relative orientations. Choosing the appropriate type and length of linker connecting the docking
peptide and substrate peptide is challenging. If the linker is too short, it could hinder the binding
of the two peptides to their respective docking sites and if the linker is longer than optimal it
may inflict an energetic penalty on the ability of the two peptides to bind to ERK. Since the
exposed surface of the ERK protein between the docking and substrate binding sites is
composed of a mixture of neutral and acidic amino acids, repeating units of the neutral,
hydrophilic molecule, 8–amino-3,6-dioxaoctanoyl (AOO) were utilized as the linker between
the substrate and docking peptides (Figure 1, panel b).
Relative Orientation of the Subcomponents of the Designed Peptides
Crystal structures of docking peptides bound to ERK show the docking peptides with an amino
to carboxy orientation (Figure 2, panel a). While no structures are available of ERK bound to
a substrate peptide, the structure of a closely related kinase, CDK2, bound to a peptide is
available (Figure 1, panel b) (43). If the orientation of a peptide substrate bound to ERK is
similar to that bound to CDK2 then the C-terminus of the docking peptide would extend from
the N-terminus of the substrate when attached via an appropriate length linker (dock-linker-
substrate). Surprisingly, another order for the connection of the substrate and docking peptides
is supported in the literature. Data from Bardwell and colleagues demonstrated that on average,
a greater percentage of solid-support bound substrate peptide (PLSP) was phosphorylated by
ERK when a docking peptide was attached to the C-terminus of the peptide compared to
substrate with an N-terminal docking peptide (29). Thus, a second order of the peptides is
possible in which the N-terminus of the docking peptide could extend from the C-terminus of
the substrate peptide when attached via a suitable linker (substrate-linker-dock).
Description of the Designed ERK Substrates
Since two orders were possible to bridge the docking peptide and substrate peptides, modular
peptide substrates with each of the three selected docking sequences were synthesized in both
orders (Table 1). From the crystallographic structures, the estimated maximal distance between
the termini of the docking and substrate peptides was 30 Å. Three AOO repeats with an
extended length of 30 Å were utilized as a linker between the docking and substrate peptides.
Two control substrate peptides were also utilized for these studies (Table 1). The first peptide,
referred to as ERKsub was the substrate sequence, TGPLSPGPF, without a docking peptide.
The second control peptide termed SCRAMMEK2 possessed a C-terminal, substrate peptide.
A linker with 3 AOO units was placed onto the N terminus of the substrate. At the N-terminus
of the linker was a peptide with the same amino acids as the docking peptide derived from
MEK2 but with the amino acids in a randomized sequence.
Phosphorylation of the Designed Substrates by ERK
To determine whether the designed substrates were phosphorylated with greater efficiency than
the substrate peptide alone, the peptides (1 μM) were incubated with ERK kinase in the presence
of ATP and Mg2+. At varying times, aliquots of the reaction mixtures were removed and the
amount of phosphorylated peptide was measured using laser-induced capillary electrophoresis
and/or a fluorescence anisotropy assay. The peptides fell into two clear groups, one in which
all of the peptide was phosphorylated within 60 min and a second group in which less than
20% of the peptide was phosphorylated after 120 min (Figure 3). The first group with rapid
phosphorylation was comprised entirely of the designed peptides with an N-terminal docking
sequence. The group with the slower phosphorylation was composed of the peptides with a C-
terminal docking peptide, the substrate alone, and the peptide with the N-terminal randomized
docking sequence. The addition of any of the docking peptides to the N-terminus of the linker-
substrate peptide dramatically enhanced phosphorylation of the modular substrate peptide.
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When the STE7 sequence was used as the docking peptide N-terminal to the substrate, the most
rapid peptide phosphorylation was obtained with nearly 100% of the peptide phosphorylated
in 10 min. The STE7 peptide potentiated the rate of phosphorylation more than either the MEK1
or MEK2 sequences. This result is consistent with existing data demonstrating that the protein
STE7 possesses a higher affinity for mammalian ERK compared to either the MEK1 and MEK2
proteins (28). In contrast, addition of the docking peptides to the C-terminus of the substrate-
linker peptide resulted in a similar or increased time for phosphorylation compared to the
substrate alone. Since a C-terminal docking peptide was ineffective, regardless of intrinsic
affinity, in enhancing phosphorylation, there was a clear preferred orientation for the docking
peptide with respect to the substrate peptide. Because the control peptide SCRAMMEK2 was
phosphorylated at similar rates compared to that of the substrate peptide alone, an amino acid
composition (but not sequence) identical to that of a docking peptide was not sufficient to
confer the enhanced rate of phosphorylation.
Apparent KM (KMapp) of the Designed Substrates for ERK
The designed peptides possess two binding sites to the kinase. Steady-state kinetics were used
to model the binding of the designed peptides to the kinase and subsequent phosphorylation
and release of the peptide (Supplementary Scheme 1). The equation for the reaction velocity
(v) vs. the concentration of the docked substrate peptide ([D-S]) could be reduced to the form:
v = Vmaxapp*[D-S]/(KMapp + [D-S]) for KMapp defined as the apparent KM and Vmax app defined
as the apparent Vmax. The reaction velocity at varying [D-S] was measured for each of the
substrates and fit to the above equation to derive a KMapp and Vmaxapp (Table 2). The v vs. [D-
S] plots for all substrates irrespective of whether the docking peptide was on the N-terminus
or C terminus were well fit by this equation (Figure 4). The substrates with N-terminal docking
peptides from the MEK1, MEK2, and ELK proteins possessed a KMapp that was over twenty-
fold better than the KM of the substrate alone. Thus docking sequences from either upstream
kinases for ERK or downstream substrates of ERK improved the properties of the substrate
peptide. The addition of the STE7 docking peptide to the substrate increased the KMapp of the
substrate by over 200 fold compared to the KM for ERKSub. Remarkably all of these N-
terminal docking sequences conferred a similar or better affinity constant (KMapp) to the
substrate peptide compared to the KM of the full-length parent protein (from which the docking
peptide were derived). These dramatic affinity enhancements suggested that the docking
peptide dominated the on and/or off rates of the designed substrates for ERK. The substrate
with the N-terminal randomized MEK2 sequence possessed a KMapp similar to the KM of the
substrate alone again suggesting that the correct order of the amino acids in the docking peptide
was critical for binding to ERK and not for turnover. The designed substrates with the C-
terminal docking peptides all possessed poorer KMapp than the KM of the substrate peptide
alone. The docking peptide in this instance may have compromised substrate access to the
catalytic cleft of the kinase.
kcatapp of the Designed Peptide Substrates for ERK
The kcatapp for the designed substrates was calculated from the Vmaxapp and the measured
enzyme concentration (Table 2). The kcatapp of all of the designed substrates was decreased
but within a factor of two of the kcat of the substrate alone. Neither the identity nor location
(N-terminal or C terminal) of the docking peptide substantially influenced the kcatapp. The
substrate peptide attached to the randomized MEK2 sequence also possessed a similar
kcatapp to that of the designed substrates with docking peptides. Thus, the decreased kcatapp of
the designed peptides was most likely not a result of the binding of a docking peptide to ERK.
In addition, the kcatapp of the designed peptides as well as ERKsub was similar to that reported
for other peptide substrates for ERK (Supplementary Table 1). To further assess the effects of
the docking peptide on the activity of the kinase, the rate of phosphorylation of ERKsub was
measured in the presence and absence of free MEK1 docking peptide. The progress of the
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reaction was nearly identical for free docking peptide at concentrations between 0 and 300
μM (Figure 5). Thus, the binding of the docking peptide to ERK does not appear to modulate
the activity of ERK as had been suggested in the literature(44). The small decrease in the
kcatapp of the docked substrates relative to the kcat of the free substrate may be the result of
steric hindrance created by the additional amino acid residues near the substrate. These results
suggest that the substrate peptide rather than the docking peptide dominated the kinetics of the
phosphate transfer.
Apparent Efficiency of the Designed Peptide Substrates for ERK
The apparent efficiency (kcatapp /KMapp) was calculated for each of the substrates in order to
compare their suitability as substrates for ERK (Table 2). The efficiency of the designed
substrates with the docking peptide on the C terminus and of the control substrate,
SCRAMMEK2, was equivalent to or less than that of the substrate peptide alone. In contrast
when the docking peptides were placed at the N terminus, the efficiency was improved by over
an order of magnitude. Remarkably the STE7 docking peptide improved the efficiency by 150
fold. Compared to other peptide substrates for ERK reported in the literature, the kcatapp /
KMapp for STE7ERK was 1000-fold improved (Supplementary Table 1). Addition of a docking
sequence can offer substantial improvements to the efficiency of a substrate peptide. A
comparison of the efficiency of the designed peptide substrate with known protein substrates
of ERK revealed that the apparent efficiency (kcatapp /KMapp) of the designed peptide
STE7ERK is similar to or better than that of many protein substrates (Supplementary Table
2).
Specificity of Designed Substrates for ERK
ERKsub can be phosphorylated by p38α MAP kinase with a KM of 1200 + 600 μM and kcat
of 570 min−1. To determine whether the designed substrates could also be phosphorylated by
p38α, the reaction velocity was measured for varying concentrations of either MEK1ERK or
MEK2ERK. As with the phosphorylation reaction with ERK, the plots of velocity vs. substrate
concentration were used to derive a KMapp and kcatapp of the designed substrates for p38α. Both
the MEK1 and MEK2-derived docking peptides improved the KMapp for p38α (Table 3).
However the KMapp of the designed substrates for p38α remained an order of magnitude greater
than that for ERK. Thus the designed substrates retained their greater affinity for ERK relative
to p38α MAP kinase. The kcatapp of MEK1ERK and MEK2ERK for p38α kinase was not
substantially improved relative to the kcat of p38α kinase for ERKSub. As with ERK, the
docking peptide dominated the binding properties (KMapp) of the designed substrates for
p38α kinase but the substrate peptide dominated the rate of phosphorylation.
Conclusion
A peptide docking sequence derived from either a downstream substrate or upstream activator
was appended to an ERK substrate peptide to yield a high efficiency substrate for ERK without
loss of specificity. In addition to the MAP kinases, a multitude of other kinases rely on docking
interactions with their protein substrates at sites which are distinct from the substrate’s
phospho-acceptor site. Protein tyrosine kinases such as ABL and Src possess SH2 domains
which recognize a phosphotyrosine motif on their substrate (45). Peptides matching these
motifs (pTyr-Glu-Glu-Ile for Src and pTyr-Asp-X-Pro for ABL) bind to the kinases with
excellent affinity and thus are suitable candidates for linkage to substrate motifs. Protein kinase
C and protein kinase A also incorporate interaction domains for binding partners and peptides
binding to these interaction domains might serve as tools to improve the efficiency of substrate
peptides (46). Consequently appending small docking peptides to kinase substrate motifs may
be a general strategy by which simple, modular yet high efficiency substrates can be constructed
for kinases.
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Competent E coli cells (strain BL21 DE3) were obtained from Invitrogen. Ni-NTA agarose
columns were from Qiagen, while fused silica capillaries were obtained from Polymicro
Technologies. All other reagents were from Sigma-Aldrich Chemical Co.
Expression and Purification of Active ERK1 and p38α
Competent E coli cells (strain BL21 DE3, Invitrogen) were transformed by electroporation in
the presence of a plasmid containing the gene for ampicillin resistance, active MEK-1R4F, and
the His6 tagged ERK1 enzyme (pETHis6MEK1 R4F+ERK1 plasmid). Expressed MEK-1R4F
phosphorylates and activates ERK1 in vivo and the hexahistidine tag (His6) aids in the
purification of ERK1 (47). The transformed bacteria were plated on dishes containing Luria
broth (LB) and ampicillin and incubated at 37 ºC overnight. On day 2, 100 mL of Terrific broth
(TB) containing ampicillin (100 μgmL−1) was inoculated with a colony of the transformed
bacteria and the culture was incubated by shaking overnight at 37 ºC. On day 3, 25 mL of the
overnight culture was added to 4 flasks each containing 1 L of TB plus ampicillin (100
μgmL−1). The cultures were grown at 30 ºC and induced with 0.3 mM isopropyl-β-D-thio
galactopyranoside (IPTG) when the optical density at 600 nm reached 0.4. Cultures were then
incubated for 12–16 hrs. The cells were harvested by centrifugation at 5000 x g for 10 min.
The cell pellets were resuspended in cold sonication buffer (50 mM NaPO4, 0.3 M NaCl, pH
8.0) containing the protease inhibitors, leupeptin (1 μgmL−1), anti-trypsin (4 μgmL−1) and 100
μM phenyl methyl sulfonyl fluoride(47) The cells were lysed in a French press (Thermo
Electron Corp). The cell lysate was clarified by centrifugation at 10,000 x g for 60 min at 4 ºC.
The active ERK1 protein was purified using a Ni-NTA agarose column (Qiagen). The protein
was dialyzed against buffer containing 12.5 mM HEPES (pH 7.3), 100 mM KCl, 6.25% (v/v)
glycerol and 0.5 mM DTT at 4 ºC. After dialysis the protein was concentrated by centrifugation
through a filter (Centricon-10, Milllipore-Amicon) and aliquoted into volumes of 20 μL and
stored at −70 ºC. Active p38α kinase was expressed and purified in an identical fashion but
using the plasmid, pETHis6/MEK6DD+p38α.
Peptide Synthesis and Preparation
Peptides labeled on the amino terminus with fluorescein and amidated on the carboxy terminus
were synthesized and purified by Anaspec Inc.. The molecular weight of the peptide was
verified by mass spectroscopy. All peptides were dissolved in water, aliquoted and stored at
−70° C. The concentration of the peptides was determined by performing amino acid analysis
in the presence of a standard by the Molecular Structure Facility at the University of California
in Davis(48).
Measurement of Peptide Phosphorylation
The Immobilized Metal Ion Affinity-Based Fluorescence Polarization (IMAP) assay
(Molecular Devices Corp.) was used to measure the amount of phosphorylated peptide in
reaction mixtures (49). The IMAP assay measures the change in anisotropy when a
phosphorylated peptide binds to a metal nanoparticle. A calibration curve was constructed by
measuring the anisotropy of solutions with known ratios of phosphorylated to non
phosphorylated peptide. The standard with 100% phosphorylated peptide was prepared using
ERK1 kinase and the percentage phosphorylation was verified by capillary electrophoresis
(40) Anisotropy was measured using a fluorescence plate reader (SpectraMax M5, Molecular
Devices) with an excitation of 485 nm (bandwidth of 9 nm) and emission of 525 nm (bandwidth
of 15 nm).
Fernandes et al. Page 7














Protein kinase assays were performed at 30ºC in assay buffer [10 mM Tris HCl (pH 7.2), 1
mM DTT, 0.01 %Tween 20 and 0.05% NaN3] with 10 mM MgCl2and 1 mM ATP and 1nM
ERK1 or 0.7nM p38α kinase in a total reaction volume of 100μL. Substrate concentrations
ranged from 3–600 μM. Aliquots of 5 μl were removed from the reaction mixture at 5, 10, 20,
40 and 60, and 120 minute intervals. The reactions were stopped by boiling at 90 ºC for 4 mins.
The amount of phosphorylation was measured using the IMAP assay as described above. In
order to validate the IMAP assay some of the samples were also analyzed using capillary
electrophoresis (Supplementary information).
Determination of Reaction Constants
The reaction velocity was determined from mixtures in which less than 10% of the substrate
was consumed. The velocity was plotted against the substrate concentration. Fits to the data
were performed using Origin 7.5 (OrginLab Corp.)
Measurement of the Concentration of Active ERK1 and p38α MAP Kinase
The concentration of active ERK1 was estimated by measuring the kinetic constants of the
ERK substrate peptide, TGPLSPGPF, under the following conditions, 20 mM Tris (pH 8.0),
200μM ATP, 1 mM DTT, 1 mM benzamidine, 10 mM MgCl2 at 30 ºC for which the peptide
ERKtide (ATGPLSPGPFGRR) has kinetic parameters of KM = 450 ± 230 μM, kcat = 120 ± 8
min−1 for ERK2 (35). The activity of p38α MAP kinase was calculated by measuring the kinetic
constants of the Cantley peptide (Fl-GIPTSPITTTYFFFKKK) under the following conditions,
0.1 M HEPES (pH 7.6), 1 mM ATP, 10 mM MgCl2, 10% glycerol, 30 ºC) for which it has the
reported kinetic parameters, KM = 103 ± 16 μM, kcat = 22.8 ± 1.2 s−1 (50)
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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A linker is required to connect the docking peptide to the substrate sequence. a) Structure of
ERK2 (PDB 2FYS) indicating the residues interacting with the substrate D domain (green),
substrate sequence (blue), and ATP (red). The image was created with Pymol (DeLano
Scientific LLC). b) Shown is the linker AOO3 with a glycine at both termini (Gly-(AOO)3-
Gly).
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Location of the docking peptide and substrate peptide when bound to the kinase. a) Model of
ERK2 (PDB 2FYS) with a docking peptide (green) depicted in a stick form. The docking
peptide GIMLRRLQKGNLPVRAL is derived from the D-domain of MAP kinase phosphatase
3 (18). The N terminus is marked with an “N”. b) Model of CDK2 (PDB 1QMZ) with a substrate
peptide (HHASPRK) depicted in a stick form (blue). The C terminus of the substrate peptide
is labeled. In a) and b), the ATP-interacting residues of the kinase are highlighted in red. All
images were generated with Pymol.
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Phosphorylation of the designed substrates by ERK1. The designed substrates (1μM) were
incubated with ERK1 in the presence of ATP and Mg2+. Aliquots of the reaction mixture were
removed at varying time points and the amount of phosphorylated peptide was measured. The
data points represent the average of three measurements and the error bars indicate their
standard deviation.
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The rates of phosphorylation of the designed substrates fit to an equation of the form v =
Vmaxapp*[D-S]/(KMapp + [D-S]) where [D-S] is the concentration of the docked substrate
peptide. a) Shown is the v vs substrate concentration ([S]) curve for ERKSub. b) and c), Shown
is the v vs docked substrate concentration ([D-S]) curve for ERKMEK1 (B) and MEK1ERK
(C). The solid lines represent the fits to the Michaelis-Menten equation (a) or the equation
above (b and c). The initial velocity v is reported per μmole of enzyme used.
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Time course of ERKSub phosphorylation by ERK in the presence and absence of the free
MEK1 docking peptide. The initial concentration of ERKSub was 150 μM. The data points
represent the average of three measurements while the error bars represent the standard
deviation.
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Table 1
Designed peptide substrates for ERK
Amino acid sequence
Substrate Name Docking motif Linker Between Peptides Consensus motif
ERKSub TGPLSPGPFc
SCRAMMEK2 a LIPALRNMVRPKLTPA b(AOO)3 TGPLSPGPF
c
ELKERK a PQKGRKPRDLELPL (AOO)3 TGPLSPGPFc
MEK1ERK a MPKKKPTPIQLNP (AOO)3 TGPLSPGPFc
MEK2ERK a MLARRKPVLPALTINP (AOO)3 TGPLSPGPFc
STE7ERK a FQRKTLQRRNLKGLNLNL (AOO)3 TGPLSPGPFc
Consensus motif Linker Between Peptides Docking motif
ERKMEK1 a TGPLSPGPF (AOO)3 MPKKKPTPIQLNPc
ERKMEK2 a TGPLSPGPF (AOO)3 MLARRKPVLPALTINPc
ERKSTE7 a TGPLSPGPF (AOO)3 FQRKTLQRRNLKGLNLNLc
a
The amino terminus was covalently attached to fluorescein
b
(AOO) is the linker, 8-amino-3,6-dioxaocatanoyl which connects the docking motif peptide to the consensus motif peptide
c
The carboxy terminus was amidated.
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Table 2
Reaction constants of the designed peptides for ERK
Peptide KM or KM




ERKSub 127 ± 17 250 ± 20 1.9
SCRAMMEK2 96 ± 36 130 ± 30 1.3
ERKMEK1 344 ± 7.4 170 ± 10 0.5
ERKMEK2 338 ± 73 180 ± 20 0.5
ERKSTE7 173 ± 47 160 ± 70 1.0
ELKERK 4.4 ± 3.1 140 ± 20 32
MEK1ERK 3.7 ± 3.3 120 ± 40 32
MEK2ERK 5.6 ± 4.9 140 ± 60 25
STE7ERK 0.6 ± 0.4 170 ± 40 280
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Table 3
Reaction constants of the designed peptides for p38α
Peptide KM or KM




ERKSub 1200 + 600 570 + 185 0.5
MEK1ERK 65 + 14 570 + 28 8.7
MEK2ERK 30 + 10 1000 + 42 33
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